Prostate Cancer Diagnostics
Prostate Cancer Diagnostics
Advertisement
John Sfakianos, MDUrothelial Carcinoma Diagnostics | May 5, 2025
John P. Sfakianos, MD, discusses the history and use of ctDNA in the GU oncology field.
View More
Simpa Salami, MD, MPHProstate Cancer Diagnostics | May 5, 2025
Dr. Salami explains how updated guideline approaches shared decision-making in higher-risk groups.
Julian Hong, MDProstate Cancer Diagnostics | April 11, 2025
Dr. Hong reviews relevant key findings from clinical trials for oligometastatic disease.
Julian Hong, MDProstate Cancer Diagnostics | April 11, 2025
Dr. Hong reviews the criteria used to determine which patients may benefit from MDT.
Carissa Chu, MDProstate Cancer Diagnostics | April 9, 2025
Dr. Chu highlights how PSMA PET is transforming perioperative prostate cancer care, including improving surgical precision.
Thomas Hope, MDProstate Cancer Diagnostics | March 31, 2025
Dr. Hope evaluates PSMA PET vs SPECT imaging for tracking therapy response in prostate cancer.
Wolfgang Fendler, MDProstate Cancer Diagnostics | March 31, 2025
Dr. Fendler reviews a multi-center study that used prognostic nomograms to risk-stratify patients based on OS.
Jérémie Calais, MD, PhDRLT | March 26, 2025
Dr. Calais provides an overview of this year's PSMA and Beyond conference agenda.
Louise Emmett, MDProstate Cancer Diagnostics | March 24, 2025
Dr. Emmett discusses the Co-PSMA trial, comparing ⁶⁴Cu-SAR-bisPSMA and ⁶⁸Ga-PSMA-11 for detecting prostate cancer ...
Emily MenendezProstate Cancer Diagnostics | March 13, 2025
Germline genetic testing is underused for patients with prostate cancer, despite many being eligible for the procedure.
Emily MenendezProstate Cancer Diagnostics | January 28, 2025
Patients with metastatic PCa are recommended to undergo both germline and somatic DNA sequencing using panel-based assays.
Jacob Ark, MDCRPC | February 3, 2025
Expert panel discusses diagnostic criteria, precision medicine, and PSMA imaging in managing metastatic prostate cancer.
Brandon TwyfordProstate Cancer Diagnostics | January 24, 2025
The FDA's Fast Track Designation enables expedited development of 64Cu-SAR-bisPSMA for recurrent prostate cancer imaging.
Rafael Sanchez-Salas, MDLocalized | January 21, 2025
Dr. Sanchez-Salas comments on whether PSMA PET is useful for determining optimal candidates for focal therapy.
Jihad Kaouk, MDLocalized | January 21, 2025
Dr. Kaouk presented on the benefits of surgery for managing biochemically recurrent prostate cancer post-radiation.
Ian Thompson, Jr., MDLocalized | January 21, 2025
Dr. Thompson, Jr. highlights his recently published large dataset of long-term complications of prostate cancer treatment.
Emily MenendezmHSPC | January 15, 2025
Conventional imaging may understage patients with HR nmHSPC compared to PSMA-PET imaging.
Akhil Abraham Saji, MDLocalized | January 14, 2025
Drs. Saji and Lebastchi explore focal therapy, covering its historical evolution, techniques, and energy modalities.
David Morris, MD, FACSProstate Cancer Diagnostics | January 6, 2025
Dr. David Morris discusses the emerging role of copper-based PSMA imaging agents, specifically 64Cu-SAR-bisPSMA.
Laura LitwinProstate Cancer | January 6, 2025
Clarity Pharmaceuticals announced that the first two participants in Co-PSMA have been dosed with its proprietary medication.
Advertisement
Advertisement